RESUMEN
Palmitoylethanolamide (PEA) emerged over the years as a promising approach in the management of chronic pain. Despite the fact that the efficacy of micron-size PEA formulations appears to be time-dependent, the optimal timing has not yet been elucidated. This systematic review and meta-analysis aim to estimate the possible advantage of an extended treatment in the relief of chronic pain. The literature search was conducted consulting scientific databases, to identify clinical trials in which micron-size PEA was administered for at least 60 days, and pain assessed by the Visual Analogue Scale (VAS) or Numeric Rating Scale (NRS). Nine studies matched the required criteria, for a total of 742 patients involved. The meta-analysis showed a statistically and clinically significant pain intensity reduction after 60 days of micron-size PEA supplementation, compared to 30 days (1.36 points, p < 0.01). The secondary analysis revealed a weighted NRS/VAS score decrease of 2.08 points within the first month of treatment. These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month. Overall, these results confirm the clinically relevant and time-depended pain-relieving effect of micron-size PEA and therefore the advantage of an extended treatment, especially in patient with incomplete pain management.
Asunto(s)
Amidas , Dolor Crónico , Etanolaminas , Ácidos Palmíticos , Ácidos Palmíticos/administración & dosificación , Ácidos Palmíticos/uso terapéutico , Humanos , Amidas/administración & dosificación , Etanolaminas/administración & dosificación , Dolor Crónico/tratamiento farmacológico , Dimensión del Dolor , Administración Oral , Resultado del Tratamiento , Analgésicos/administración & dosificaciónRESUMEN
OBJECTIVE: The management of chronic prostatitis/ chronic pelvic pain syndrome type III (CP/CPPS) has been always considered complex due to several biopsychological factors underlying the disease. In this clinical study, we aimed to evaluate the efficacy of the treatment with Palmitoylethanolamide, Epilobium and Calendula extract in patients with CP/CPPS III. MATERIALS AND METHODS: From June 2023 to July 2023, we enrolled 45 consecutive patients affected by CP/CPPS type III in three different institution. We included patients aged between 18 and 75 years with symptoms of pelvic pain for 3 months or more before the study, a total National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score ≥ 12 point and diagnosed with NIH category III, according to 4-glass test Meares-Stamey test. Patients were then allocated to receive rectal suppositories of PEA, Epilobium and Calendula, 1 suppository/ die for 1 month. All patients have been tested with standard urinalysis in order to assess urinary leukocytes (U-WBC). The primary endpoint of the study was the reduction of NIHCPSI. The secondary outcomes were the change of peak flow, post-void residual (PVR), IIEF-5, VAS score, PSA and decrease of U-WBC. RESULTS: A total of 45 patients concluded the study protocol. At baseline, the median age of all the patients included in the cohort was 49 years, the median PSA was 2.81 ng/ml, the median NIH-CPSI was 18.55, the median IIEF-5 was 18.27, the median U-WBC was 485.3/mmc, the median VAS score was 6.49, the median PVR was 26.5 ml and the median peak flow was 16.3 ml/s. After 1 month of therapy we observed a statistically significant improvement of NIH-CPSI, U-WBC, PSA, IIEF-5, peak flow, PVR and VAS. CONCLUSIONS: In this observational study, we showed the clinical efficacy of the treatment with PEA, Epilobium and Calendula, 1 suppository/die for 1 month, in patients with CP/CPPS III. The benefits of this treatment could be related to the reduction of inflammatory cells in the urine that could imply a reduction of inflammatory cytokines. These results should be confirmed in further studies with greater sample size.
Asunto(s)
Amidas , Calendula , Epilobium , Etanolaminas , Ácidos Palmíticos , Extractos Vegetales , Prostatitis , Humanos , Masculino , Persona de Mediana Edad , Adulto , Prostatitis/tratamiento farmacológico , Supositorios , Amidas/administración & dosificación , Amidas/uso terapéutico , Anciano , Ácidos Palmíticos/administración & dosificación , Ácidos Palmíticos/uso terapéutico , Resultado del Tratamiento , Adulto Joven , Etanolaminas/administración & dosificación , Etanolaminas/uso terapéutico , Extractos Vegetales/administración & dosificación , Extractos Vegetales/uso terapéutico , Adolescente , Enfermedad Crónica , Dolor Pélvico/tratamiento farmacológico , Dolor Pélvico/etiologíaAsunto(s)
Antiasmáticos , Asma , Etanolaminas , Fumarato de Formoterol , Humanos , Asma/tratamiento farmacológico , Fumarato de Formoterol/administración & dosificación , Fumarato de Formoterol/uso terapéutico , Antiasmáticos/uso terapéutico , Antiasmáticos/administración & dosificación , Etanolaminas/uso terapéutico , Etanolaminas/administración & dosificación , Corticoesteroides/administración & dosificación , Corticoesteroides/uso terapéutico , Administración por Inhalación , Medicina Basada en la Evidencia , Broncodilatadores/uso terapéutico , Broncodilatadores/administración & dosificación , Resultado del TratamientoRESUMEN
BACKGROUND: Artemether-lumefantrine is widely used for uncomplicated Plasmodium falciparum malaria; sulfadoxine-pyrimethamine plus amodiaquine is used for seasonal malaria chemoprevention. We aimed to determine the efficacy of artemether-lumefantrine with and without primaquine and sulfadoxine-pyrimethamine plus amodiaquine with and without tafenoquine for reducing gametocyte carriage and transmission to mosquitoes. METHODS: In this phase 2, single-blind, randomised clinical trial conducted in Ouelessebougou, Mali, asymptomatic individuals aged 10-50 years with P falciparum gametocytaemia were recruited from the community and randomly assigned (1:1:1:1) to receive either artemether-lumefantrine, artemether-lumefantrine with a single dose of 0·25 mg/kg primaquine, sulfadoxine-pyrimethamine plus amodiaquine, or sulfadoxine-pyrimethamine plus amodiaquine with a single dose of 1·66 mg/kg tafenoquine. All trial staff other than the pharmacist were masked to group allocation. Participants were not masked to group allocation. Randomisation was done with a computer-generated randomisation list and concealed with sealed, opaque envelopes. The primary outcome was the median within-person percent change in mosquito infection rate in infectious individuals from baseline to day 2 (artemether-lumefantrine groups) or day 7 (sulfadoxine-pyrimethamine plus amodiaquine groups) after treatment, assessed by direct membrane feeding assay. All participants who received any trial drug were included in the safety analysis. This study is registered with ClinicalTrials.gov, NCT05081089. FINDINGS: Between Oct 13 and Dec 16, 2021, 1290 individuals were screened and 80 were enrolled and randomly assigned to one of the four treatment groups (20 per group). The median age of participants was 13 (IQR 11-20); 37 (46%) of 80 participants were female and 43 (54%) were male. In individuals who were infectious before treatment, the median percentage reduction in mosquito infection rate 2 days after treatment was 100·0% (IQR 100·0-100·0; n=19; p=0·0011) with artemether-lumefantrine and 100·0% (100·0-100·0; n=19; p=0·0001) with artemether-lumefantrine with primaquine. Only two individuals who were infectious at baseline infected mosquitoes on day 2 after artemether-lumefantrine and none at day 5. By contrast, the median percentage reduction in mosquito infection rate 7 days after treatment was 63·6% (IQR 0·0-100·0; n=20; p=0·013) with sulfadoxine-pyrimethamine plus amodiaquine and 100% (100·0-100·0; n=19; p<0·0001) with sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine. No grade 3-4 or serious adverse events occurred. INTERPRETATION: These data support the effectiveness of artemether-lumefantrine alone for preventing nearly all mosquito infections. By contrast, there was considerable post-treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine; therefore, the addition of a transmission-blocking drug might be beneficial in maximising its community impact. FUNDING: Bill & Melinda Gates Foundation.
Asunto(s)
Amodiaquina , Antimaláricos , Combinación Arteméter y Lumefantrina , Combinación de Medicamentos , Fluorenos , Malaria Falciparum , Plasmodium falciparum , Primaquina , Pirimetamina , Sulfadoxina , Humanos , Antimaláricos/uso terapéutico , Antimaláricos/administración & dosificación , Pirimetamina/uso terapéutico , Pirimetamina/administración & dosificación , Amodiaquina/uso terapéutico , Amodiaquina/administración & dosificación , Sulfadoxina/uso terapéutico , Sulfadoxina/administración & dosificación , Masculino , Adulto , Femenino , Adolescente , Niño , Malaria Falciparum/transmisión , Malaria Falciparum/prevención & control , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/epidemiología , Método Simple Ciego , Persona de Mediana Edad , Primaquina/uso terapéutico , Primaquina/administración & dosificación , Combinación Arteméter y Lumefantrina/uso terapéutico , Combinación Arteméter y Lumefantrina/administración & dosificación , Adulto Joven , Fluorenos/administración & dosificación , Fluorenos/uso terapéutico , Malí/epidemiología , Plasmodium falciparum/efectos de los fármacos , Artemisininas/administración & dosificación , Artemisininas/uso terapéutico , Aminoquinolinas/administración & dosificación , Aminoquinolinas/uso terapéutico , Aminoquinolinas/efectos adversos , Etanolaminas/administración & dosificación , Etanolaminas/uso terapéutico , Animales , Quimioterapia CombinadaRESUMEN
BACKGROUND: Sixty-five percent of people with severe asthma and a fractional exhaled nitric oxide (Feno) greater than or equal to 45 parts per billion (ppb) are nonadherent to inhaled corticosteroids (ICSs). Digital devices recording both time of use and inhaler technique identify nonadherence and ICS responsiveness but are not widely available. As the NEXThaler dose counter activates only at an inspiratory flow rate of 35 L/min, this may provide an alternative to identifying ICS responsiveness. OBJECTIVE: To assess ICS adherence and responsiveness in severe asthma using beclometasone/formoterol (200/6 µg) NEXThaler (BFN) dose-counting. METHODS: Patients with severe asthma with a Feno greater than or equal to 45 ppb were invited to use BFN in place of their usual ICS/long-acting ß2-agonist. Feno, 6-item Asthma Control Questionnaire score, lung function, and blood eosinophil count were monitored for 3 months. A log10ΔFeno of greater than or equal to 0.24 was used to define Feno suppression as the primary marker of ICS responsiveness at day 28. RESULTS: Twenty-seven of 48 (56%) patients demonstrated significant Feno suppression at month 1 (median pre-114, post-48 ppb, P < .001). A small but significant reduction occurred in Feno nonsuppressors. The 6-item Asthma Control Questionnaire score fell a median 1.2 units in Feno suppressors (P < .001) and 0.5 units in nonsuppressors (P = .025). These effects were sustained until month 3 in Feno suppressors, with a significant improvement in FEV1 and blood eosinophils. Sixty-seven percent (18 of 27) of those with baseline ICS/long-acting ß2-agonist prescription refills of 80% or more were Feno suppressors, suggesting prior nonadherence despite adequate prescription collection. Seventy-nine percent of Feno suppressors did not require biologics within mean 11.4 months from initial dose counting. CONCLUSIONS: BFN dose-counting identifies ICS responsiveness in severe asthma with the implication that these patients may not need to progress to biological therapies.
Asunto(s)
Antiasmáticos , Asma , Beclometasona , Fumarato de Formoterol , Óxido Nítrico , Humanos , Asma/tratamiento farmacológico , Masculino , Fumarato de Formoterol/administración & dosificación , Fumarato de Formoterol/uso terapéutico , Femenino , Beclometasona/administración & dosificación , Beclometasona/uso terapéutico , Persona de Mediana Edad , Óxido Nítrico/metabolismo , Óxido Nítrico/análisis , Adulto , Administración por Inhalación , Antiasmáticos/uso terapéutico , Antiasmáticos/administración & dosificación , Cumplimiento de la Medicación , Etanolaminas/uso terapéutico , Etanolaminas/administración & dosificación , Corticoesteroides/uso terapéutico , Corticoesteroides/administración & dosificación , Anciano , Combinación de Medicamentos , Resultado del Tratamiento , Eosinófilos/inmunología , Pruebas de Función RespiratoriaRESUMEN
Dysregulation of circadian rhythm can cause nocturia. Levels of fatty acid metabolites, such as palmitoylethanolamide (PEA), 9-hydroxy-10E,12Z-octadecadienoic acid (9-HODE), and 4-hydroxy-5E,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid (4-HDoHE), are higher in the serum of patients with nocturia; however, the reason remains unknown. Here, we investigated the circadian rhythm of fatty acid metabolites and their effect on voiding in mice. WT and Clock mutant (ClockΔ19/Δ19) mice, a model for nocturia with circadian rhythm disorder, were used. Levels of serum PEA, 9-HODE, and 4-HDoHEl were measured every 8 h using LC/MS. Voiding pattern was recorded using metabolic cages after administration of PEA, 9-HODE, and 4-HDoHE to WT mice. Levels of serum PEA and 9-HODE fluctuated with circadian rhythm in WT mice, which were lower during the light phase. In contrast, circadian PEA and 9-HODE level deteriorated or retreated in ClockΔ19/Δ19 mice. Levels of serum PEA, 9-HODE, and 4-HDoHE were higher in ClockΔ19/Δ19 than in WT mice. Voiding frequency increased in PEA- and 4-HDoHE-administered mice. Bladder capacity decreased in PEA-administered mice. The changes of these bladder functions in mice were similar to those in elderly humans with nocturia. These findings highlighted the novel effect of lipids on the pathology of nocturia. These may be used for development of biomarkers and better therapies for nocturia.
Asunto(s)
Ácidos Grasos/metabolismo , Nocturia/genética , Nocturia/metabolismo , Amidas/administración & dosificación , Amidas/sangre , Animales , Proteínas CLOCK/genética , Ritmo Circadiano , Modelos Animales de Enfermedad , Ácidos Docosahexaenoicos/administración & dosificación , Ácidos Docosahexaenoicos/sangre , Etanolaminas/administración & dosificación , Etanolaminas/sangre , Ácidos Grasos/administración & dosificación , Inyecciones Intraperitoneales , Ácidos Linoleicos Conjugados/administración & dosificación , Ácidos Linoleicos Conjugados/sangre , Masculino , Ratones Endogámicos C57BL , Nocturia/sangre , Ácidos Palmíticos/administración & dosificación , Ácidos Palmíticos/sangre , Fotoperiodo , Vejiga Urinaria/patología , Micción/genéticaRESUMEN
The mechanisms of NASH development in the context of age and genetics are not fully elucidated. This study investigates the age-dependent liver defects during NASH development in mice with heterozygous deletion of Pcyt2 (Pcyt2+/-), the rate limiting enzyme in phosphatidylethanolamine (PE) synthesis. Further, the therapeutic potential of Pcyt2 substrate, phosphoethanolamine (PEtn), is examined. Pcyt2+/- were investigated at 2 and 6-8 months (mo) of age and in addition, 6-mo old Pcyt2+/- with developed NASH were supplemented with PEtn for 8 weeks and glucose and fatty acid metabolism, insulin signaling, and inflammation were examined. Heterozygous ablation of Pcyt2 causes changes in liver metabolic regulators from young age, prior to the development of liver disease which does not occur until adulthood. Only older Pcyt2+/- experiences perturbed glucose and fatty acid metabolism. Older Pcyt2+/- liver develops NASH characterized by increased glucose production, accumulation of TAG and glycogen, and increased inflammation. Supplementation with PEtn reverses Pcyt2+/- steatosis, inflammation, and other aspects of NASH, showing that was directly caused by Pcyt2 deficiency. Pcyt2 deficiency is a novel mechanism of metabolic dysregulation due to reduced membrane ethanolamine phospholipid synthesis, and the metabolite PEtn offers therapeutic potential for NASH reversion.
Asunto(s)
Etanolaminas/administración & dosificación , Resistencia a la Insulina , Enfermedad del Hígado Graso no Alcohólico/enzimología , ARN Nucleotidiltransferasas/deficiencia , Envejecimiento , Animales , Ácidos Grasos/metabolismo , Glucosa/metabolismo , Ratones , Ratones Noqueados , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Enfermedad del Hígado Graso no Alcohólico/genética , Enfermedad del Hígado Graso no Alcohólico/metabolismo , ARN Nucleotidiltransferasas/genéticaRESUMEN
Causing more and more deaths, stroke has been a leading cause of death worldwide. However, success in clinical stroke trials has remained elusive. N-oleoylethanolamine (OEA) was an endogenous highly hydrophobic molecule with outstanding neuroprotective effect. In this article, hydrogen bonds were successfully formed between OEA and soybean phosphatidylcholine (SPC). The synthetic OEA-SPC complex and DSPE-PEG were self-assembled into liposomes (OEA NPs), with OEA-SPC loaded in the core and PEG formed a hydrophilic shell. Hence, highly hydrophobic OEA was loaded into liposomes as amorphous state with a drug loading of 8.21 ± 0.18 wt%. With fairly uniform size and well-distributed character, the OEA NPs were systemically assessed as an intravenous formulation for stroke therapy. The results indicated that the administration of OEA NPs could significantly improve the survival rate and the Garcia score of the MCAO rats compared with free OEA. The TTC-stained brain slices declared that the cerebral infarct volume and the edema degree induced by MCAO could be decreased to an extremely low level via the administration of OEA NPs. The Morris water maze (MWM) test suggested that the spatial learning and memory of the MCAO rats could also be ameliorated by OEA NPs. The immunofluorescence assay stated that the apoptosis of the neurons and the inflammation within the brain were greatly inhibited. The results suggest that the OEA NPs have a great chance to develop OEA as a potential anti-stroke formulation for clinic application.
Asunto(s)
Portadores de Fármacos/química , Endocannabinoides/administración & dosificación , Endocannabinoides/farmacología , Etanolaminas/administración & dosificación , Etanolaminas/farmacología , Liposomas/química , Ácidos Oléicos/administración & dosificación , Ácidos Oléicos/farmacología , Accidente Cerebrovascular/tratamiento farmacológico , Animales , Química Farmacéutica , Modelos Animales de Enfermedad , Liberación de Fármacos , Interacciones Hidrofóbicas e Hidrofílicas , Masculino , Fosfatidilcolinas/química , Fosfatidiletanolaminas/química , Polietilenglicoles/química , Ratas , Ratas Sprague-DawleyRESUMEN
Novel treatment strategies are urgently required for osteoarthritis (OA). Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide with analgesic and anti-inflammatory effects. We aimed to examine its effect on OA and elucidate the molecular mechanism of actions in monosodium iodoacetate (MIA)-induced OA Sprague-Dawley rats. The experimental animals were divided into normal control group (injected with saline + treated with phosphate-buffered saline (PBS), NOR), control group (injected with MIA + treated with PBS, CON), 50 or 100 mg/kg body weight (BW)/day PEA-treated group (injected with MIA + treated with 50 or 100 mg of PEA/kg BW/day, PEA50 or PEA100), and positive control group (injected with MIA + treated with 6 mg of diclofenac/kg BW/day, DiC). The changes in blood parameters, body parameters, gene expression of inflammatory mediators and cytokines, knee thickness, and joint tissue were observed. Oral administration of PEA had no adverse effects on the BW, liver, or kidneys. PEA reduced knee joint swelling and cartilage degradation in MIA-induced OA rats. The serum levels of leukotriene B4, nitric oxide, tumor necrosis factor (TNF)-α, interleukin (IL)-1ß, and prostaglandin E2 considerably reduced in the PEA100 group compared with those in the CON group. In the synovia of knee joints, the mRNA expression of iNOS, 5-Lox, Cox-2, Il-1ß, Tnf-α, and Mmp-2, -3, -9, and -13 apparently increased with MIA administration. Meanwhile, Timp-1 mRNA expression apparently decreased in the CON group but increased to the normal level with PEA treatment. Thus, PEA can be an effective therapeutic agent for OA.
Asunto(s)
Amidas/farmacología , Antiinflamatorios/farmacología , Artritis Experimental/tratamiento farmacológico , Etanolaminas/farmacología , Osteoartritis/tratamiento farmacológico , Ácidos Palmíticos/farmacología , Administración Oral , Amidas/administración & dosificación , Animales , Antiinflamatorios/administración & dosificación , Relación Dosis-Respuesta a Droga , Etanolaminas/administración & dosificación , Ácido Yodoacético , Articulación de la Rodilla/efectos de los fármacos , Articulación de la Rodilla/patología , Masculino , Ácidos Palmíticos/administración & dosificación , Ratas , Ratas Sprague-DawleyRESUMEN
OBJECTIVE: Increasing scalp hair fullness is a global unmet consumer need. An approach to decrease hair shedding by reducing scalp stratum corneum oxidation via a combination of antioxidant and barrier-enhancing technologies has been previously demonstrated. The purpose of this study was to test the effectiveness of the individual antioxidant piroctone olamine in two different product forms (shampoo or leave-on product) for activity to improve hair retention. METHODS: Female subjects with self-perceived hair thinning participated in an 8-week, double-blind, placebo-controlled, randomized clinical study to evaluate either a piroctone olamine (PO) containing shampoo or a PO containing leave on treatment, each relative to their corresponding placebo formulation Too many periods. Results for phototrichograms, TEWL, and biomarker analysis of scalp condition for the shampoo treatments are discussed. Phototrichogram results are shared for the assessment of the leave on treatment. RESULTS: Statistically significant increases in hair amount were observed by phototrichogram after use of both PO-containing products versus placebo formulations. The PO shampoo treatment also significantly decreased oxidative stress on the hair and scalp, and improved scalp condition as assessed by TEWL and scalp biomarker values. CONCLUSION: These results illustrate the effectiveness of a cosmetic antioxidant to improve scalp condition thereby improving hair retention. The observed improvements in scalp condition are consistent with previous reports with other antioxidant technologies and suggest that the hair retention effect was achieved by preventing oxidative damage to the scalp.
Asunto(s)
Alopecia/tratamiento farmacológico , Antioxidantes/uso terapéutico , Etanolaminas/uso terapéutico , Preparaciones para el Cabello/uso terapéutico , Piridonas/uso terapéutico , Cuero Cabelludo/efectos de los fármacos , Administración Tópica , Adulto , Anciano , Antioxidantes/administración & dosificación , Método Doble Ciego , Combinación de Medicamentos , Etanolaminas/administración & dosificación , Femenino , Preparaciones para el Cabello/administración & dosificación , Humanos , Persona de Mediana Edad , Piridonas/administración & dosificaciónRESUMEN
This study aimed to assess the neuro-regenerative properties of co-ultramicronized PEALut (Glialia®), composed of palmitoylethanolamide (PEA) and the flavonoid luteolin (Lut), in an in vivo model of traumatic brain injury (TBI) and patients affected by moderate TBI. An increase in neurogenesis was seen in the mice at 72 h and 7 d after TBI. The co-ultra PEALut treatment helped the neuronal reconstitution process to restore the basal level of both novel and mature neurons; moreover, it induced a significant upregulation of the neurotrophic factors, which ultimately led to progress in terms of memory recall during behavioral testing. Moreover, our preliminary findings in a clinical trial suggested that Glialia® treatment facilitated neural recovery on working memory. Thus, co-ultra PEALut (Glialia®) could represent a valuable therapeutic agent for intensifying the endogenous repair response in order to better treat TBI.
Asunto(s)
Amidas/administración & dosificación , Lesiones Traumáticas del Encéfalo/tratamiento farmacológico , Etanolaminas/administración & dosificación , Luteolina/administración & dosificación , Neurogénesis/efectos de los fármacos , Ácidos Palmíticos/administración & dosificación , Administración Oral , Adulto , Anciano , Amidas/farmacología , Animales , Lesiones Traumáticas del Encéfalo/etiología , Lesiones Traumáticas del Encéfalo/psicología , Modelos Animales de Enfermedad , Quimioterapia Combinada , Etanolaminas/farmacología , Femenino , Humanos , Luteolina/farmacología , Masculino , Memoria a Corto Plazo/efectos de los fármacos , Ratones , Persona de Mediana Edad , Prueba del Laberinto Acuático de Morris/efectos de los fármacos , Ácidos Palmíticos/farmacología , Distribución Aleatoria , Aprendizaje Espacial/efectos de los fármacos , Resultado del TratamientoRESUMEN
OBJECTIVE: Approximately 30% of patients with confirmed COVID-19 report persistent smell or taste disorders as long-term sequalae of infection. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is associated with inflammatory changes to the olfactory bulb, and treatments with anti-inflammatory properties are hypothesized to attenuate viral injury and promote recovery of olfaction after infection. Our study investigated the efficacy of a supplement with Palmitoylethanolamide (PEA) and Luteolin to support recovery of olfaction in COVID-19 patients. PATIENTS AND METHODS: We conducted a randomized-controlled pilot study in outpatients with history of confirmed COVID-19 with post-infection olfactory impairment that persisted ≥ 90 days after SARS-CoV-2 negative testing. Patients were randomized to two times a day olfactory rehabilitation alone or weekly olfactory rehabilitation plus daily oral supplement with PEA and Luteolin. Subjects with preexisting olfactory disorders were excluded. Sniffin' Sticks assessments were performed at baseline and 30 days after treatment. Data on gender, age, and time since infection were collected. Kruskal-Wallis (KW) test was used to compare variances of Sniff scores between groups over time, and Spearman's correlation coefficients were calculated to assess for correlations between Sniff Score and gender or duration of infection. RESULTS: Among 12 patients enrolled (n=7, supplement; n=5, controls), patients receiving supplement had greater improvement in olfactory threshold, discrimination, and identification score versus controls (p=0.01). Time since infection was negatively correlated with Sniff Score, and there was no correlation between gender. CONCLUSIONS: Treatment combining olfactory rehabilitation with oral supplementation with PEA and Luteolin was associated with improved recovery of olfactory function, most marked in those patients with longstanding olfactory dysfunction. Further studies are necessary to replicate these findings and to determine whether early intervention including olfactory rehabilitation and PEA+Luteolin oral supplement might prevent SARS-CoV-2 associated olfactory impairment.
Asunto(s)
Amidas/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Antivirales/administración & dosificación , Tratamiento Farmacológico de COVID-19 , Etanolaminas/administración & dosificación , Luteolina/administración & dosificación , Trastornos del Olfato/tratamiento farmacológico , Ácidos Palmíticos/administración & dosificación , Adulto , COVID-19/complicaciones , COVID-19/diagnóstico , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos del Olfato/diagnóstico , Trastornos del Olfato/etiología , Proyectos Piloto , Método Simple Ciego , Olfato/efectos de los fármacos , Olfato/fisiologíaRESUMEN
BACKGROUND: An increasing number of studies have investigated the adverse effect profile of oral cannabinoids; however, few studies have provided sufficient data on the tolerability of topical cannabinoids in human participants. AIM: To assess the tolerability profile of several commercial topical formulations containing cannabidiol (CBD) and palmitoylethanolamide (PEA) on the skin of healthy human participants. METHODS: Three human clinical trials and one in vitro study were conducted. The potential for skin irritation, sensitization and phototoxicity of several products, were assessed via patch testing on healthy human skin. The products assessed included two formulations containing CBD and PEA, one containing hemp seed oil and four concentrations of CBD alone. Ocular toxicity was tested using a traditional hen's egg chorioallantoic membrane model with three CBD, PEA and hemp seed oil formulations. RESULTS: There was no irritation or sensitization of the products evident via patch testing on healthy participants. Additionally, mild phototoxicity of a hemp seed oil product was found at the 48-h time point compared with the negative control. The in vitro experiment demonstrated comparable effects of cannabinoid products with historically nonirritating products. CONCLUSION: These specific formulations of CBD- and PEA-containing products are nonirritating and nonsensitizing in healthy adults, and further encourage similar research assessing their long-term safety and efficacy in human participants with dermatological diseases. There are some limitations to the study: (i) external validity may be limited as formulations from a single manufacturer were used for this study, while vast heterogeneity exists across unregulated, commercial CBD products on the market; and (ii) products were assessed only on normal, nondiseased human skin, and therefore extrapolation to those with dermatological diseases cannot be assumed.
Asunto(s)
Amidas/efectos adversos , Cannabidiol/efectos adversos , Cannabis/efectos adversos , Dermatitis Irritante/etiología , Dermatitis Fototóxica/etiología , Etanolaminas/efectos adversos , Ácidos Palmíticos/efectos adversos , Extractos Vegetales/efectos adversos , Administración Tópica , Amidas/administración & dosificación , Cannabidiol/administración & dosificación , Membrana Corioalantoides/efectos de los fármacos , Etanolaminas/administración & dosificación , Humanos , Técnicas In Vitro , Ácidos Palmíticos/administración & dosificación , Extractos Vegetales/administración & dosificación , Método Simple CiegoRESUMEN
BACKGROUND: The neurologic complications of rheumatic diseases (RDs) are highly variable, and their manifestations are linked to the pathogenesis and clinical phenotype of the specific RDs. In rheumatoid arthritis, for example, the peripheral nervous system is most commonly involved and mononeuritis multiplex, nerve entrapment and vasculitic sensorimotor neuropathies are not uncommon. Often the therapy for these disorders is not easy and is characterized by the use of different drugs. Palmitoylethanolamide (PEA) has been tested in a wide variety of animal models and has been evaluated in several clinical studies for nerve compression syndromes, demonstrating that PEA acts as an effective and safe analgesic compound. Acetyl-L-Carnitine (ALC) has also been shown to be an effective and safe treatment in painful peripheral neuropathy. In the last years the synergistic effect between PEA and ALC has been demonstrated. The aim of our study was to evaluate the efficacy of supplementation of standard therapy (STh) with Kalanit® (Chiesi Italia Spa; Parma, Italy) in patients with peripheral neuropathy secondary to RDs. METHODS: Patients at the time of enrollment were affected by RDs with neuropathy from <12 months, documented by electromyography. The analyzed patients were treated with the STh chosen according to their rheumatic disease (RA or SpA) and for their neuropathy (e.g. analgesic, NSAIDs, pregabalin or gabapentin) as per clinical practice. The sample was divided into 2 groups: group 1, patients treated with STh, to which a fixed combination of PEA (600 mg) + ALC (500 mg) (Kalanit®) was added twice a day for 2 weeks and then once a day for 6 months; group 2, patients treated only with STh. Each patient underwent clinical evaluations and questionnaires were administered in order to evaluate their neuropathy and the efficacy of the therapy. RESULTS: In group 1, 18 patients suffering from sciatic pain, 16 patients from carpal tunnel syndrome and 8 patients with peripheral neuropathy of the lower limbs were included and PEA + ALC FC was added to STh. These patients were compared with patients from group 2, who had the same pathology and demographic characteristics: 20 patients with sciatic pain, 15 with carpal tunnel syndrome and 5 with peripheral neuropathy of the lower limbs, respectively; this group was treated with STh only. Patients treated with PEA + ALC FC had a significant improvement in pain VAS compared to patients treated with group 2 in all the diseases analyzed (P value: sciatic pain 0.032, carpal tunnel syndrome 0.025 and lower limbs neuropathy 0.041). Patients in group 1 showed a significant improvement compared to patients treated in group 2 also from a specific score. Specifically, LBP-IQ showed significant improvement in group one (P value: 0.031), as did CHFD (P=0.011) and NPQ (P=0.025). CONCLUSIONS: The synergistic effect of PEA and ALC seems to have a further advantage in the treatment of this type of pathology, including the anti-inflammatory effect but also in terms of therapy optimization and therefore of better adherence to treatments. Our study shows that it is important to identify the type of pain to follow an accurate diagnostic algorithm, considering the clinical characteristics of the patient and carefully evaluate the indication, preferring a multimodal approach.
Asunto(s)
Acetilcarnitina/uso terapéutico , Amidas/uso terapéutico , Analgésicos no Narcóticos/uso terapéutico , Etanolaminas/uso terapéutico , Ácidos Palmíticos/uso terapéutico , Enfermedades del Sistema Nervioso Periférico/tratamiento farmacológico , Enfermedades Reumáticas/complicaciones , Acetilcarnitina/administración & dosificación , Anciano , Amidas/administración & dosificación , Analgésicos no Narcóticos/administración & dosificación , Síndrome del Túnel Carpiano/tratamiento farmacológico , Síndrome del Túnel Carpiano/etiología , Esquema de Medicación , Combinación de Medicamentos , Etanolaminas/administración & dosificación , Femenino , Humanos , Extremidad Inferior/inervación , Masculino , Persona de Mediana Edad , Neuralgia/tratamiento farmacológico , Ácidos Palmíticos/administración & dosificación , Enfermedades del Sistema Nervioso Periférico/etiología , Enfermedades Reumáticas/tratamiento farmacológico , Neuropatía Ciática/tratamiento farmacológico , Neuropatía Ciática/etiologíaRESUMEN
Coronavirus Disease 2019 (COVID-19) is upsetting the world and innovative therapeutic solutions are needed in an attempt to counter this new pandemic. Great hope lies in vaccines, but drugs to cure the infected patient are just as necessary. In the most severe forms of the disease, a cytokine storm with neuroinflammation occurs, putting the patient's life at serious risk, with sometimes long-lasting sequelae. Palmitoylethanolamide (PEA) is known to possess anti-inflammatory and neuroprotective properties, which make it an ideal candidate to be assumed in the earliest stage of the disease. Here, we provide a mini-review on the topic, pointing out phospholipids consumption in COVID-19, the possible development of an antiphospholipid syndrome secondary to SARS-CoV-2 infection, and reporting our preliminary single-case experience concerning to a 45-year-old COVID-19 female patient recently treated with success by micronized / ultramicronized PEA.
Asunto(s)
Amidas/administración & dosificación , Antiinflamatorios/administración & dosificación , Síndrome Antifosfolípido/tratamiento farmacológico , Tratamiento Farmacológico de COVID-19 , Etanolaminas/administración & dosificación , Fármacos Neuroprotectores/administración & dosificación , Ácidos Palmíticos/administración & dosificación , SARS-CoV-2/metabolismo , Síndrome Antifosfolípido/etiología , Síndrome Antifosfolípido/metabolismo , Síndrome Antifosfolípido/patología , COVID-19/complicaciones , COVID-19/metabolismo , COVID-19/patología , Femenino , Humanos , Persona de Mediana EdadRESUMEN
The prevalence of periodontal disease poses a significant global health burden. Treatments for these diseases, primarily focused on removal and eradication of dental plaque biofilms, are challenging due to limited access to periodontal pockets where these oral pathogens reside. Herein, we report on the development and characterization of nitric oxide (NO)-releasing carboxymethylcellulose (CMC) derivatives and evaluate their in vitro bactericidal efficacy against planktonic Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, two prominent periodontopathogens. Bactericidal exposure assays revealed that three of the synthesized NO-releasing polymers were capable of reducing bacterial viability of both species by 99.9% in 2 hr at concentrations of 4 mg ml-1 or lower, reflecting NO's potent and rapid bactericidal action. The NO-releasing CMCs elicited minimal toxicity to human gingival fibroblasts at their bactericidal concentrations following 24-hr exposure.
Asunto(s)
Aggregatibacter actinomycetemcomitans/efectos de los fármacos , Antibacterianos/farmacología , Compuestos Azo/farmacología , Carboximetilcelulosa de Sodio , Etanolaminas/farmacología , Óxido Nítrico/farmacología , Enfermedades Periodontales/microbiología , Poliaminas/farmacología , Porphyromonas gingivalis/efectos de los fármacos , Propilaminas/farmacología , Antibacterianos/administración & dosificación , Compuestos Azo/administración & dosificación , Compuestos Azo/química , Biopolímeros , Línea Celular , Diaminas/química , Portadores de Fármacos , Sistemas de Liberación de Medicamentos , Etanolaminas/administración & dosificación , Etanolaminas/química , Fibroblastos/efectos de los fármacos , Encía/citología , Humanos , Estructura Molecular , Óxido Nítrico/administración & dosificación , Óxido Nítrico/toxicidad , Poliaminas/administración & dosificación , Poliaminas/química , Propilaminas/administración & dosificación , Propilaminas/química , Especificidad de la Especie , ViscosidadRESUMEN
BACKGROUND & AIMS: Acid hypersensitivity is claimed to be a symptomatic trigger in functional dyspepsia (FD); however, the neuroimmune pathway(s) and the mediators involved in this process have not been investigated systematically. Palmitoylethanolamide (PEA) is an endogenous compound, able to modulate nociception and inflammation, but its role in FD has not been assessed. METHODS: Duodenal biopsy specimens from FD and control subjects, and peroxisome proliferator-activated receptor-α (PPARα) null mice were cultured at a pH of 3.0 and 7.4. Mast cell (MC) number, the release of their mediators, and the expression of transient receptor potential vanilloid receptor (TRPV)1 and TRPV4, were evaluated. All measurements also were performed in the presence of a selective blocker of neuronal action potential (tetradotoxin). FD and control biopsy specimens in acidified medium also were incubated in the presence of different PEA concentrations, alone or combined with a selective PPARα or PPAR-γ antagonist. RESULTS: An acid-induced increase in MC density and the release of their mediators were observed in both dyspeptic patients and controls; however, this response was amplified significantly in FD. This effect was mediated by submucosal nerve fibers and up-regulation of TRPV1 and TRPV4 receptors because pretreatment with tetradotoxin significantly reduced MC infiltration. The acid-induced endogenous release of PEA was impaired in FD and its exogenous administration counteracts MC activation and TRPV up-regulation. CONCLUSIONS: Duodenal acid exposure initiates a cascade of neuronal-mediated events culminating in MC activation and TRPV overexpression. These phenomena are consequences of an impaired release of endogenous PEA. PEA might be regarded as an attractive therapeutic strategy for the treatment of FD.
Asunto(s)
Amidas/metabolismo , Duodeno/patología , Dispepsia/inmunología , Etanolaminas/metabolismo , Mucosa Intestinal/patología , Mastocitos/inmunología , Ácidos Palmíticos/metabolismo , Adulto , Amidas/administración & dosificación , Animales , Biopsia , Estudios de Casos y Controles , Modelos Animales de Enfermedad , Duodeno/química , Duodeno/inmunología , Duodeno/metabolismo , Dispepsia/genética , Dispepsia/metabolismo , Dispepsia/patología , Etanolaminas/administración & dosificación , Femenino , Ácido Gástrico/metabolismo , Voluntarios Sanos , Humanos , Concentración de Iones de Hidrógeno , Mucosa Intestinal/química , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Masculino , Mastocitos/metabolismo , Ratones , Ratones Noqueados , Persona de Mediana Edad , PPAR alfa/genética , PPAR alfa/metabolismo , Ácidos Palmíticos/administración & dosificación , Canales Catiónicos TRPV/metabolismo , Técnicas de Cultivo de TejidosRESUMEN
Neuroinflammation is a physiological response aimed at maintaining the homodynamic balance and providing the body with the fundamental resource of adaptation to endogenous and exogenous stimuli. Although the response is initiated with protective purposes, the effect may be detrimental when not regulated. The physiological control of neuroinflammation is mainly achieved via regulatory mechanisms performed by particular cells of the immune system intimately associated with or within the nervous system and named "non-neuronal cells." In particular, mast cells (within the central nervous system and in the periphery) and microglia (at spinal and supraspinal level) are involved in this control, through a close functional relationship between them and neurons (either centrally, spinal, or peripherally located). Accordingly, neuroinflammation becomes a worsening factor in many disorders whenever the non-neuronal cell supervision is inadequate. It has been shown that the regulation of non-neuronal cells-and therefore the control of neuroinflammation-depends on the local "on demand" synthesis of the endogenous lipid amide Palmitoylethanolamide and related endocannabinoids. When the balance between synthesis and degradation of this bioactive lipid mediator is disrupted in favor of reduced synthesis and/or increased degradation, the behavior of non-neuronal cells may not be appropriately regulated and neuroinflammation exceeds the physiological boundaries. In these conditions, it has been demonstrated that the increase of endogenous Palmitoylethanolamide-either by decreasing its degradation or exogenous administration-is able to keep neuroinflammation within its physiological limits. In this review the large number of studies on the benefits derived from oral administration of micronized and highly bioavailable forms of Palmitoylethanolamide is discussed, with special reference to neuroinflammatory disorders.
Asunto(s)
Amidas/administración & dosificación , Amidas/metabolismo , Etanolaminas/administración & dosificación , Etanolaminas/metabolismo , Inflamación/dietoterapia , Enfermedades del Sistema Nervioso/tratamiento farmacológico , Enfermedades Neurodegenerativas/tratamiento farmacológico , Ácidos Palmíticos/administración & dosificación , Ácidos Palmíticos/metabolismo , Enfermedad de Alzheimer/dietoterapia , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/metabolismo , Esclerosis Amiotrófica Lateral/dietoterapia , Esclerosis Amiotrófica Lateral/tratamiento farmacológico , Esclerosis Amiotrófica Lateral/metabolismo , Animales , Trastorno del Espectro Autista/dietoterapia , Trastorno del Espectro Autista/tratamiento farmacológico , Trastorno del Espectro Autista/metabolismo , Endocannabinoides/metabolismo , Humanos , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Redes y Vías Metabólicas , Esclerosis Múltiple/dietoterapia , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple/metabolismo , Enfermedades del Sistema Nervioso/dietoterapia , Enfermedades del Sistema Nervioso/metabolismo , Enfermedades Neurodegenerativas/dietoterapia , Enfermedades Neurodegenerativas/metabolismo , Dolor/dietoterapia , Dolor/tratamiento farmacológico , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/metabolismoRESUMEN
BACKGROUND: Postoperative pain (PO) is a common form of acute pain. Inadequate PO treatment is an important health problem, as it leads to worse outcomes, such as chronic post-surgical pain. Therefore, it is necessary to acquire new knowledge on PO mechanisms to develop therapeutic options with greater efficacy than those available today and to lower the risk of adverse effects. For this reason, we evaluated the ability of micronized palmitoylethanolamide (PEA-m) to resolve the pain and inflammatory processes activated after incision of the hind paw in an animal model of PO. METHODS: The animals were subjected to surgical paw incision and randomized into different groups. PEA-m was administered orally at 10 mg/kg at different time points before or after incision. RESULTS: Our research demonstrated that the pre- and post-treatment with PEA-m reduced the activation of mast cells at the incision site and the expression of its algogenic mediator nerve growth factor (NGF) in the lumbar spinal cord. Furthermore, again at the spinal level, it was able to decrease the activation of phospho-extracellular signal-regulated kinases (p-ERK), ionized calcium binding adaptor molecule 1 (Iba1), glial fibrillary acidic protein (GFAP), and the expression of brain-derived neurotrophic factor (BDNF). PEA-m also reduced the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) spinal pathway, showing a protective effect in a rat model of PO. CONCLUSION: The results obtained reinforce the idea that PEA-m may be a potential treatment for the control of pain and inflammatory processes associated with PO. In addition, pre- and post-treatment with PEA-m is more effective than treatment alone after the surgery and this limits the time of taking the compound and the abuse of analgesics.
Asunto(s)
Amidas/administración & dosificación , Amidas/uso terapéutico , Etanolaminas/administración & dosificación , Etanolaminas/uso terapéutico , Dolor Postoperatorio/tratamiento farmacológico , Ácidos Palmíticos/administración & dosificación , Ácidos Palmíticos/uso terapéutico , Sustancias Protectoras/uso terapéutico , Amidas/farmacología , Animales , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Proteínas de Unión al Calcio , Etanolaminas/farmacología , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Proteína Ácida Fibrilar de la Glía/metabolismo , Hiperalgesia/complicaciones , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/fisiopatología , Vértebras Lumbares/metabolismo , Vértebras Lumbares/patología , Vértebras Lumbares/fisiopatología , Masculino , Mastocitos/efectos de los fármacos , Proteínas de Microfilamentos , Actividad Motora/efectos de los fármacos , FN-kappa B/metabolismo , Factor de Crecimiento Nervioso/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Dolor Postoperatorio/complicaciones , Dolor Postoperatorio/fisiopatología , Ácidos Palmíticos/farmacología , Fosforilación/efectos de los fármacos , Sustancias Protectoras/farmacología , Ratas Sprague-DawleyRESUMEN
Glaucoma, a leading cause of irreversible blindness worldwide, is an optic neuropathy characterized by the progressive death of retinal ganglion cells (RGCs). Elevated intraocular pressure (IOP) is recognized as the main risk factor. Despite effective IOP-lowering therapies, the disease progresses in a significant number of patients. Therefore, alternative IOP-independent strategies aiming at halting or delaying RGC degeneration is the current therapeutic challenge for glaucoma management. Here, we review the literature on the neuroprotective activities, and the underlying mechanisms, of natural compounds and dietary supplements in experimental and clinical glaucoma.